Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Axitinib
Drug ID BADD_D00193
Description Axitinib is a second generation tyrosine kinase inhibitor that works by selectively inhibiting vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2, VEGFR-3).[L6676] Through this mechanism of action, axitinib blocks angiogenesis, tumour growth and metastases. It is reported to exhibit potency that is 50-450 times higher than that of the first generation VEGFR inhibitors.[L6676] Axitinib is an indazole derivative.[A179398] It is most commonly marketed under the name Inlyta® and is available in oral formulations.
Indications and Usage Used in kidney cell cancer and investigated for use/treatment in pancreatic and thyroid cancer.
Marketing Status Prescription
ATC Code L01EK01
DrugBank ID DB06626
KEGG ID D03218
MeSH ID D000077784
PubChem ID 6450551
TTD Drug ID D01ZRI
NDC Product Code 54893-0043; 68554-0088; 54893-0032; 65344-0033; 63539-044; 0069-0151; 0069-0145; 63539-026
Synonyms Axitinib | AG 013736 | AG013736 | AG-013736 | Inlyta
Chemical Information
Molecular Formula C22H18N4OS
CAS Registry Number 319460-85-0
SMILES CNC(=O)C1=CC=CC=C1SC2=CC3=C(C=C2)C(=NN3)C=CC4=CC=CC=N4
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Sinus disorder22.04.06.0020.000533%
Respiratory tract infection22.07.07.001; 11.01.08.017--Not Available
Unevaluable event08.01.03.051--Not Available
Hypophagia19.09.01.004; 14.03.01.006; 07.01.06.0100.002931%Not Available
Blood count abnormal13.01.07.001--Not Available
Osteonecrosis of jaw24.04.05.005; 15.02.04.010--
Chronic kidney disease20.01.03.017--
Bone marrow failure01.03.03.0050.001865%
Thyroid cancer16.24.03.001; 05.02.05.0010.000208%Not Available
Pharyngeal disorder22.04.05.0070.000533%Not Available
Organising pneumonia22.01.02.0080.000278%Not Available
Renal cell carcinoma20.01.04.003; 16.08.02.0020.007367%Not Available
Oropharyngeal pain22.02.05.022; 07.05.05.0040.005328%
Acute kidney injury20.01.03.016--
Posterior reversible encephalopathy syndrome17.13.02.0070.005595%
Drug-induced liver injury12.03.01.044; 09.01.07.023--Not Available
Hepatic cancer09.04.02.008; 16.07.02.0040.000139%Not Available
Pneumocystis jirovecii pneumonia11.03.07.005; 22.07.08.0090.000139%Not Available
Candida infection11.03.03.0210.001066%
Immune thrombocytopenic purpura10.04.01.008; 01.08.01.0070.000533%Not Available
Multiple organ dysfunction syndrome08.01.03.057--
Appendicitis perforated11.01.07.028; 07.04.06.0110.000799%
Eczema asteatotic23.03.04.0250.000533%Not Available
Pneumothorax spontaneous22.05.02.0070.000533%Not Available
Renal cancer stage IV20.01.04.014; 16.08.02.0080.000139%Not Available
Renal cell carcinoma stage IV16.08.02.010; 20.01.04.0160.000139%Not Available
Tumour embolism24.01.01.034; 16.32.03.0300.000799%Not Available
Renal cancer metastatic20.01.04.012; 16.08.02.0060.001181%Not Available
Pulmonary cavitation22.01.02.0220.000533%Not Available
Lymphangiosis carcinomatosa24.09.02.007; 16.22.02.009; 01.09.01.0270.000139%Not Available
The 18th Page    First    Pre   18 19    Next   Last    Total 19 Pages